DE2604844C3 - Verfahren zum Nachweis von Hepatitis B-Oberflächenantigen in menschlichem Blut - Google Patents
Verfahren zum Nachweis von Hepatitis B-Oberflächenantigen in menschlichem BlutInfo
- Publication number
- DE2604844C3 DE2604844C3 DE2604844A DE2604844A DE2604844C3 DE 2604844 C3 DE2604844 C3 DE 2604844C3 DE 2604844 A DE2604844 A DE 2604844A DE 2604844 A DE2604844 A DE 2604844A DE 2604844 C3 DE2604844 C3 DE 2604844C3
- Authority
- DE
- Germany
- Prior art keywords
- hepatitis
- surface antigen
- serum
- antigen
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000427 antigen Substances 0.000 title claims description 62
- 102000036639 antigens Human genes 0.000 title claims description 62
- 108091007433 antigens Proteins 0.000 title claims description 62
- 208000002672 hepatitis B Diseases 0.000 title claims description 47
- 210000004369 blood Anatomy 0.000 title claims description 24
- 239000008280 blood Substances 0.000 title claims description 24
- 238000001514 detection method Methods 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 10
- 210000002966 serum Anatomy 0.000 claims description 73
- 238000012360 testing method Methods 0.000 claims description 51
- 239000003153 chemical reaction reagent Substances 0.000 claims description 28
- 239000004816 latex Substances 0.000 claims description 28
- 229920000126 latex Polymers 0.000 claims description 28
- 239000002245 particle Substances 0.000 claims description 21
- 239000011324 bead Substances 0.000 claims description 18
- 229940039227 diagnostic agent Drugs 0.000 claims description 15
- 239000000032 diagnostic agent Substances 0.000 claims description 15
- 239000011347 resin Substances 0.000 claims description 15
- 229920005989 resin Polymers 0.000 claims description 15
- 239000004793 Polystyrene Substances 0.000 claims description 11
- 108010074605 gamma-Globulins Proteins 0.000 claims description 11
- 208000006454 hepatitis Diseases 0.000 claims description 10
- 231100000283 hepatitis Toxicity 0.000 claims description 10
- 229920002223 polystyrene Polymers 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 241000700199 Cavia porcellus Species 0.000 claims description 7
- 239000007900 aqueous suspension Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 241000700198 Cavia Species 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 4
- 229920003002 synthetic resin Polymers 0.000 claims description 4
- 239000000057 synthetic resin Substances 0.000 claims description 4
- 108010017384 Blood Proteins Proteins 0.000 claims description 3
- 102000004506 Blood Proteins Human genes 0.000 claims description 3
- 230000004520 agglutination Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 238000005199 ultracentrifugation Methods 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims 3
- 239000012736 aqueous medium Substances 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 230000005180 public health Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
- 239000007975 buffered saline Substances 0.000 description 14
- 239000004471 Glycine Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 102000007562 Serum Albumin Human genes 0.000 description 5
- 108010071390 Serum Albumin Proteins 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000012817 gel-diffusion technique Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 230000010773 Antigen Neutralization Effects 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5761—Hepatitis B
- G01N33/5764—Hepatitis B surface antigen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/550,949 US3992517A (en) | 1975-02-19 | 1975-02-19 | Detection of hepatitis B surface antigen by latex agglutination |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2604844A1 DE2604844A1 (de) | 1976-09-02 |
| DE2604844B2 DE2604844B2 (de) | 1978-01-26 |
| DE2604844C3 true DE2604844C3 (de) | 1978-09-21 |
Family
ID=24199232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2604844A Expired DE2604844C3 (de) | 1975-02-19 | 1976-02-07 | Verfahren zum Nachweis von Hepatitis B-Oberflächenantigen in menschlichem Blut |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US3992517A (enExample) |
| JP (1) | JPS51106723A (enExample) |
| AR (1) | AR210753A1 (enExample) |
| AT (1) | AT352290B (enExample) |
| BE (1) | BE838474A (enExample) |
| BR (1) | BR7600906A (enExample) |
| CH (1) | CH613048A5 (enExample) |
| CS (1) | CS188129B2 (enExample) |
| DD (1) | DD124128A5 (enExample) |
| DE (1) | DE2604844C3 (enExample) |
| DK (1) | DK144395C (enExample) |
| EG (1) | EG12696A (enExample) |
| ES (2) | ES445042A1 (enExample) |
| FI (1) | FI63493C (enExample) |
| FR (1) | FR2301825A1 (enExample) |
| GB (1) | GB1529891A (enExample) |
| IE (1) | IE42031B1 (enExample) |
| IL (1) | IL48927A (enExample) |
| IT (1) | IT1066096B (enExample) |
| LU (1) | LU74348A1 (enExample) |
| MX (1) | MX4962E (enExample) |
| NL (1) | NL7601441A (enExample) |
| NZ (1) | NZ179988A (enExample) |
| PL (1) | PL98604B1 (enExample) |
| RO (1) | RO71615A (enExample) |
| SE (1) | SE429481B (enExample) |
| SU (1) | SU1091844A3 (enExample) |
| ZA (1) | ZA76721B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1508132A (en) * | 1974-05-20 | 1978-04-19 | Technicon Instr | Analysis of biological fluids |
| IL49752A (en) * | 1975-07-09 | 1979-07-25 | Kabi Ab | Compositions having affinity for hepatitis virus and method for hepatitis virus removal or concentration |
| US4202665A (en) * | 1978-11-06 | 1980-05-13 | Albert Einstein College Of Medicine Of Yeshiva University A Division Of Yeshiva University | Detection of hepatitis B surface antigen |
| US4204989A (en) * | 1978-12-13 | 1980-05-27 | Merck & Co., Inc. | Isolation of hepatitis B e antigen |
| US4310508A (en) * | 1979-06-19 | 1982-01-12 | Siber George | Diagnostic test and reagent therefor |
| US4340564A (en) * | 1980-07-21 | 1982-07-20 | Daryl Laboratories, Inc. | Immunoadsorptive surface coating for solid-phase immunosubstrate and solid-phase immunosubstrate |
| CA1172561A (en) * | 1981-01-28 | 1984-08-14 | Richard H. Decker | Igm detection method |
| US4351824A (en) * | 1981-02-05 | 1982-09-28 | Icl Scientific | Polystyrene latex reagents, methods of preparation, and use in immunological procedures |
| US4493899A (en) * | 1981-10-16 | 1985-01-15 | City Of Hope | Method of testing for particular antibodies in the serum of a patient |
| FR2531718B1 (fr) * | 1982-08-16 | 1986-11-21 | Sanofi Sa | Reactif permettant un dosage de tres haute sensibilite de l'antigene caracteristique du virus de l'hepatite b dans les liquides biologiques humains |
| US4542103A (en) * | 1982-09-13 | 1985-09-17 | Miles Laboratories Inc. | Latex agglutination determination of IgG in neonatals and in colostrum |
| JPS60256057A (ja) * | 1984-06-01 | 1985-12-17 | Dai Ichi Pure Chem Co Ltd | 免疫学的測定法 |
| US6881536B1 (en) * | 1986-04-30 | 2005-04-19 | Bioveris Corporation | Particle based electrochemiluminescent assays |
| TW394845B (en) * | 1993-12-28 | 2000-06-21 | Ssp Co Ltd | A method for inspection of the blood ingredients and their using set |
| US6159748A (en) * | 1995-03-13 | 2000-12-12 | Affinitech, Ltd | Evaluation of autoimmune diseases using a multiple parameter latex bead suspension and flow cytometry |
| JP3840521B2 (ja) * | 1995-08-21 | 2006-11-01 | Ａｓｐｉｏｎ株式会社 | ウイルス検出方法およびウイルス検査用キット |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759948A (fr) * | 1969-12-08 | 1971-06-07 | Mc Culler James F | Procede de detection de l'hepatite infectieuse et sereuse et reactifs utilises a cet effet |
| BE787014A (fr) * | 1971-07-31 | 1973-01-31 | Pfizer | Procede et reactif pour deceler la presence de l'antigene australien |
| GB1356413A (en) * | 1971-09-09 | 1974-06-12 | Pfizer Ltd | Method of obtaining purified australia antigen from blood serum |
| JPS49126818A (enExample) * | 1973-04-13 | 1974-12-04 |
-
1975
- 1975-02-19 US US05/550,949 patent/US3992517A/en not_active Expired - Lifetime
- 1975-11-07 IE IE2435/75A patent/IE42031B1/en unknown
-
1976
- 1976-01-26 SE SE7600797A patent/SE429481B/xx not_active IP Right Cessation
- 1976-01-28 IL IL48927A patent/IL48927A/xx unknown
- 1976-02-02 MX MX763642U patent/MX4962E/es unknown
- 1976-02-07 DE DE2604844A patent/DE2604844C3/de not_active Expired
- 1976-02-09 ZA ZA721A patent/ZA76721B/xx unknown
- 1976-02-10 ES ES445042A patent/ES445042A1/es not_active Expired
- 1976-02-10 AT AT91776A patent/AT352290B/de not_active IP Right Cessation
- 1976-02-11 RO RO7684761A patent/RO71615A/ro unknown
- 1976-02-11 FI FI760326A patent/FI63493C/fi not_active IP Right Cessation
- 1976-02-12 NL NL7601441A patent/NL7601441A/xx not_active Application Discontinuation
- 1976-02-12 NZ NZ179988A patent/NZ179988A/xx unknown
- 1976-02-12 IT IT48062/76A patent/IT1066096B/it active
- 1976-02-12 BE BE1007197A patent/BE838474A/xx not_active IP Right Cessation
- 1976-02-13 DK DK60876A patent/DK144395C/da not_active IP Right Cessation
- 1976-02-13 FR FR7604009A patent/FR2301825A1/fr active Granted
- 1976-02-13 CH CH178076A patent/CH613048A5/xx not_active IP Right Cessation
- 1976-02-13 DD DD191240A patent/DD124128A5/xx unknown
- 1976-02-13 BR BR7600906A patent/BR7600906A/pt unknown
- 1976-02-13 LU LU74348A patent/LU74348A1/xx unknown
- 1976-02-13 AR AR262244A patent/AR210753A1/es active
- 1976-02-13 SU SU2322065A patent/SU1091844A3/ru active
- 1976-02-14 JP JP51015405A patent/JPS51106723A/ja active Pending
- 1976-02-14 PL PL1976187226A patent/PL98604B1/pl unknown
- 1976-02-16 CS CS76998A patent/CS188129B2/cs unknown
- 1976-02-17 EG EG90/76A patent/EG12696A/xx active
- 1976-02-18 GB GB6477/76A patent/GB1529891A/en not_active Expired
- 1976-08-27 ES ES451061A patent/ES451061A1/es not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2604844C3 (de) | Verfahren zum Nachweis von Hepatitis B-Oberflächenantigen in menschlichem Blut | |
| CH627281A5 (enExample) | ||
| EP0305337A1 (de) | Verfahren zum Nachweis von Antigenen und/oder Antikörpern sowie Testausrüstung zur Durchführung des Verfahrens | |
| DE69332236T2 (de) | Verfahren zur Dissoziierung von einem Immunokomplex und dafür verwendeter Immunoassay | |
| DE2907198C2 (enExample) | ||
| EP0001223A2 (de) | Mit einer Polyhydroxyverbindung beschichteten Latex, Verfahren zur Herstellung dieses Latex, immunologisches Reagenz enthaltend diesen Latex, Verfahren zur Herstellung dieses Reagenzes, Verwendung dieses Reagenzes, Bestimmungsverfahren unter Verwendung dieses Reagenzes und Reagenziengarnitur enthaltend dieses Reagenz. | |
| DE69008743T2 (de) | Extraktionszusammensetzung, Testsatz und deren Verwendung zum Nachweis von Herpes-Simplex-Antigen. | |
| DE3205301C2 (enExample) | ||
| DE2746101A1 (de) | Verfahren zur bestimmung von immunoglobulinen in menschlicher koerperfluessigkeit | |
| DE3105555C2 (enExample) | ||
| DE3609980A1 (de) | Verfahren zur bestimmung von haemoglobin im stuhl | |
| DE3030806A1 (de) | Verfahren zur durchfuehrung von enzymimmunobestimmungen. | |
| DE2624814C2 (de) | Verfahren und Mittel zum Nachweis oder zur Bestimmung von Antikörpern in Körperflüssigkeiten | |
| DE69200460T2 (de) | Agglutinationskomplex zum Nachweis von Blutgruppen. | |
| DE2934757C2 (de) | Zusammensetzung und Verfahren zur Bestimmung von Humanimmunglobulin-G | |
| DE2533701A1 (de) | Immunologische diagnoseprodukte | |
| DE2037507A1 (enExample) | ||
| DE2934756A1 (de) | Zusammensetzung zur bestimmung von beta 2 -humanmikroglobulin und verfahren zu deren herstellung und deren verwendung | |
| EP0009198A1 (de) | Verfahren zum Nachweis und zur Bestimmung komplementbindender Antikörper und Reagenz zur Durchführung dieses Verfahrens | |
| CH636449A5 (de) | Verfahren zur gewinnung eines neuen, spezifischen alpha-l-antikoerpers. | |
| DE2907228A1 (de) | Immunochemische bestimmung | |
| EP0554657B1 (de) | Verfahren zur Bestimmung von Antigenen oder Antikörpern in Gegenwart eines Immunkomplexes | |
| DE69127255T2 (de) | Verfahren zur Messung von menschlichem C-Peptid | |
| DE3854603T2 (de) | Teststreifen für diagnose durch multi-immunoassay system. | |
| DE2126128A1 (de) | Medizinisches Testverfahren, Reagens und Additiv zur Durchführung des Verfahrens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8339 | Ceased/non-payment of the annual fee |